Antibody Drug Conjugates Contract Manufacturing Market Analysis Report By Condition, By Linker, By Region And Segment Forecasts From 2021 To 2028

Synopsis

The global antibody drug conjugates contract manufacturing market was prized by USD 7.2 billion in 2020. It is estimated to witness 12.3% CAGR from 2021 to 2028.

Drivers

As a result of subcontracting of the services and operations to contract manufacturing organizations, increasing insist for the biologic treatment, rising occurrences of cancer, the market is expected to observe major enlargement, during the forecast period.

Several cancer medications include toxicities that source considerable side effects, restraining the prescribed amount plus effectiveness of these medicines and placing a major problem on patients. An antibody drug conjugate can assist to decrease a few of these difficulties. Antibody Drug Conjugates (ADC) facilitates the deliverance of specific medicine dose to a precise place of importance. Most frequently, they are utilized in oncology while a big prescribed amount of medicine is necessary on the tumor position but not in close by tissue.

The active pharmaceutical ingredient (API) business, which usually has been controlled by the small-molecule medicines, is fast changing in the direction of biopharmaceuticals. Likewise, the quantity of production subcontracted to contract manufacturing industry is rising.

By reason of the worries concerning intellectual possessions and the complications of manufacturing process, mainly biological are currently manufactured internally by the medicine manufacturers. This has an unplanned influence on the contract manufacturing companies.

Effect of Covid-19

The eruption of Covid-19 pandemic had a huge effect on the healthcare field. It considerably disturbed the complete supply chain, as of raw materials to manufacture in addition to delivery. Key companies of the market for antibody drug conjugates contract manufacturing are involved in partnerships, tactical agreements, research & development actions plus the presentation of new products to encounter customer necessities for diagnostics as well as medicinal apparatuses, medications and vaccines.  

Linker Insight

The cleavable linker section held the major 56.5% revenue share and led the market, in 2020. The section is expected to stay leading during the near future. The compensations that cleavable linkers get in specific situations to deliver the medicine to the object cell, is the most important factor, which affects the expansion in the section.

The individuality of the linker amid the payload and antibody are seeing to be critical to an antibody drug conjugates accomplishment. The capability of cleavable linkers to competently differentiate amid circulatory as well as target-cell conditions, justify its efficiency.

The non-cleavable linker section is expected to observe the highest 12.5% CAGR, during the forecast period. Antibody drug conjugates including non-cleavable linkers are extra dependent on the target cells' biology. On-cleavable linkers contain greater plasma constancy than cleavable linkers. This can assist to improve the healing indicator.

Condition Insight

The myeloma section held the leading 49.4% revenue share and directed the market, in 2020. The issues that affect the development of the market are antibody drug conjugates. This is a new category of medication for myeloma patients. It conveys an influential cytotoxic chemical, straight to the myeloma cell.

The specificity of the monoclonal antibody connected to the cytotoxic chemical describes the objective. This form of act decreases bystander cell harm and unlock a curative window. Antibody drug conjugates contain a greater prospective for utilize in the curing of myeloma because it is immediately available treatment. It can be use in approximately every myeloma treatment clinics as well as to a varied range of patients.

Regional Insight

In 2020, Asia Pacific held the major 46.4% revenue share and directed the antibody drug conjugates contract manufacturing market. The region is expected to observe the highest 14.6% CAGR, during the forecast period. Asia Pacific comprises 48.0% share of every fresh cancer cases in the world. China holds almost half the patients, out of all these cases.

Likewise, in Asia deaths due to the cancer hold 55.0% share of every global cancer death. The frequency of cancer and the deaths due to it are projected to rise in Asia, during the subsequently two decades. By means of enormous prospective for the commercialization and medicine research, Asia Pacific is the highest rising pharmaceutical market of the world. Therefore, pharmaceutical system within this region is attracting a lot of attention of the global pharmaceutical companies. The issue accountable for the enlargement of the market within the region is the enhancement in the subcontracting procedure to contract manufacturing companies.

Companies

To enlarge their share in the market, the major companies are taking on various plans like rising R&D actions in the part of antibody drug conjugates for cancer medications, joint ventures with new contestants of the market, mergers & acquisitions and alliances.

Some of the companies for antibody drug conjugates contract manufacturing market are:

• Piramal Pharma Solutions
• Catalent
• Samsung Biologics
• Boehringer Ingelheim
• Siegfried
• Lonza

Report Scope

Segments Covered in the Report

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2016 to 2028. For the purpose of this study, Million Insights has segmented the global antibody drug conjugates contract manufacturing market report on the basis of condition, linker, and region:

• Condition Outlook (Revenue, USD Million, 2016 - 2028)
    • Myeloma
    • Lymphoma
    • Breast Cancer
    • Others (Urothelial Cancer)

• Linker Outlook (Revenue, USD Million, 2016 - 2028)
    • Cleavable Linker
    • Non-cleavable Linker

• Regional Outlook (Revenue, USD Million, 2016 - 2028)
    • North America
        • U.S.
        • Canada
    • Europe
        • U.K.
        • Germany
        • France
        • Italy
        • Spain
    • Asia Pacific
        • Japan
        • China
        • India
        • Australia
        • South Korea
    • Latin America
        • Brazil
        • Mexico
        • Argentina
    • Middle East and Africa (MEA)
        • South Africa
        • Saudi Arabia
        • UAE